OBJECTIVE: Left ventricular dysfunction after successful cardiopulmonary resuscitation contributes to early death after resuscitation. Proinflammatory cytokines are known to decrease myocardial function, and tumor necrosis factor-alpha has been shown to increase after successful resuscitation. We hypothesized that blocking the effects of tumor necrosis factor-alpha with infliximab would prevent or minimize postresuscitation cardiac dysfunction. DESIGN: Randomized, placebo-controlled comparative study. SETTING: Large animal research laboratory. SUBJECTS: Twenty-eight anesthetized and instrumented domestic male swine (Yorkshire and Yorkshire/Hampshire mix; weight, 35-45 kg). INTERVENTIONS: Infusion of infliximab (5 mg/kg) or normal saline after resuscitation from ventricular fibrillation cardiac arrest. MEASUREMENTS AND MAIN RESULTS: Hemodynamic variables, indices of left ventricular function, and tumor necrosis factor-alpha were measured before and after 8 mins of cardiac arrest during the early postresuscitation period (3 hrs). Within 5 mins of restoration of spontaneous circulation, 14 animals received infliximab, 5 mg/kg, infused over 30 mins. Fourteen animals received an infusion of normal saline. Inotropes and vasopressors were not administered to either group after resuscitation. Tumor necrosis factor-alpha increased after restoration of circulation and remained elevated throughout the observation period. Differences between groups were not significant. Interleukin-1beta concentration did not change significantly during the observation period in either study group. Mean arterial pressure and stroke work were significantly greater in the infliximab group within 30 mins of resuscitation, and these differences were sustained throughout the 3-hr postresuscitation period. The effect of tumor necrosis factor-alpha blockade was evident only in animals with a significant increase (doubling) in plasma tumor necrosis factor-alpha at 30 mins after arrest. CONCLUSION: Tumor necrosis factor-alpha plays a role in cardiac dysfunction after arrest and infliximab may attenuate or prevent postresuscitation myocardial dysfunction when administered immediately after resuscitation.
OBJECTIVE:Left ventricular dysfunction after successful cardiopulmonary resuscitation contributes to early death after resuscitation. Proinflammatory cytokines are known to decrease myocardial function, and tumor necrosis factor-alpha has been shown to increase after successful resuscitation. We hypothesized that blocking the effects of tumor necrosis factor-alpha with infliximab would prevent or minimize postresuscitation cardiac dysfunction. DESIGN: Randomized, placebo-controlled comparative study. SETTING: Large animal research laboratory. SUBJECTS: Twenty-eight anesthetized and instrumented domestic male swine (Yorkshire and Yorkshire/Hampshire mix; weight, 35-45 kg). INTERVENTIONS: Infusion of infliximab (5 mg/kg) or normal saline after resuscitation from ventricular fibrillation cardiac arrest. MEASUREMENTS AND MAIN RESULTS: Hemodynamic variables, indices of left ventricular function, and tumor necrosis factor-alpha were measured before and after 8 mins of cardiac arrest during the early postresuscitation period (3 hrs). Within 5 mins of restoration of spontaneous circulation, 14 animals received infliximab, 5 mg/kg, infused over 30 mins. Fourteen animals received an infusion of normal saline. Inotropes and vasopressors were not administered to either group after resuscitation. Tumor necrosis factor-alpha increased after restoration of circulation and remained elevated throughout the observation period. Differences between groups were not significant. Interleukin-1beta concentration did not change significantly during the observation period in either study group. Mean arterial pressure and stroke work were significantly greater in the infliximab group within 30 mins of resuscitation, and these differences were sustained throughout the 3-hr postresuscitation period. The effect of tumor necrosis factor-alpha blockade was evident only in animals with a significant increase (doubling) in plasma tumor necrosis factor-alpha at 30 mins after arrest. CONCLUSION:Tumor necrosis factor-alpha plays a role in cardiac dysfunction after arrest and infliximab may attenuate or prevent postresuscitation myocardial dysfunction when administered immediately after resuscitation.
Authors: E Abraham; A Anzueto; G Gutierrez; S Tessler; G San Pedro; R Wunderink; A Dal Nogare; S Nasraway; S Berman; R Cooney; H Levy; R Baughman; M Rumbak; R B Light; L Poole; R Allred; J Constant; J Pennington; S Porter Journal: Lancet Date: 1998-03-28 Impact factor: 79.321
Authors: G Nichol; P Steen; J Herlitz; L J Morrison; I Jacobs; J P Ornato; R O'Connor; V Nadkarni Journal: Resuscitation Date: 2005-06 Impact factor: 5.262
Authors: Michael Koeppen; Patrick N Harter; Stephanie Bonney; Megan Bonney; Susan Reithel; Cornelia Zachskorn; Michel Mittelbronn; Tobias Eckle Journal: Anesthesiology Date: 2012-06 Impact factor: 7.892
Authors: Scott T Youngquist; James T Niemann; Atman P Shah; Joseph L Thomas; John P Rosborough Journal: Resuscitation Date: 2013-01-09 Impact factor: 5.262
Authors: James T Niemann; Scott T Youngquist; Atman P Shah; Joseph L Thomas; John P Rosborough Journal: Resuscitation Date: 2012-06-07 Impact factor: 5.262
Authors: Derek J Hausenloy; Gary Baxter; Robert Bell; Hans Erik Bøtker; Sean M Davidson; James Downey; Gerd Heusch; Masafumi Kitakaze; Sandrine Lecour; Robert Mentzer; Mihaela M Mocanu; Michel Ovize; Rainer Schulz; Richard Shannon; Malcolm Walker; Gail Walkinshaw; Derek M Yellon Journal: Basic Res Cardiol Date: 2010-09-24 Impact factor: 17.165
Authors: Beilei Lei; Hana N Dawson; Briana Roulhac-Wilson; Haichen Wang; Daniel T Laskowitz; Michael L James Journal: J Neuroinflammation Date: 2013-08-20 Impact factor: 8.322